Abcellera Biologics Inc ABCL

$11.88 +0.75 (6.74%)

Valuation

Market cap
3,765,183,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,208,400
Avg volume
4,469,752
Day's range
$11.20 – $11.98
Shares out
306,611,000
Stochastic %K
12%
Beta
1.59
Analysts
Strong Buy
Price target
$17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

SuperGreenToday Nov 7, 1:02 AM
$ABCL Share Price: $11.89 Contract Selected: Apr 16, 2027 $10 Calls Buy Zone: $2.80 – $3.46 Target Zone: $5.05 – $6.17 Potential Upside: 70% ROI Time to Expiration: 159 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
ElongTSLA Nov 6, 11:41 PM
$ABCL There are a lot of interesting catalysts for November specifically. I'm particularly interested in the earnings call, and also the November 16 and November 17 Institutional Investor Engagements. @Stocktradesmoon thanks for putting this on my radar. I think there is a lot of upside on ABCL.
1 replies
Stocktradesmoon Nov 6, 8:36 PM
$ABCL Phenotype of a company that has the potential to scale up and be the next $REGN $VRTX $LLY $PFE 1. Needs a blockbuster that it wholly owns 2. Capabilities internally to reproducibly develop drugs 3. Pipeline to show its worth more than a single asset - Carl Hansen
0 replies
Stocktradesmoon Nov 6, 8:08 PM
$ABCL ❤️ $REGN $PFE $SLS $MRNA WHO’S EXCITED 😆 for NEXT WEEK?!!!! 😊 ABcellera 🔥!!! 👀🚀 👀🚨 4 MAJOR Catalyst Events All HAPPENING in a few days!! 👀👏🚀 — November could be more important than the recent share price rally. Here’s exactly what I’m watching. November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London. AND… We got MORE NEWS 🗞️ YESTERDAY After-Hours!! + ABcellera to Present @ the UBS GLOBAL BIOPHARMA Conference on November 17, 2026!!
0 replies
Stocktradesmoon Nov 6, 8:02 PM
$ABCL ❤️ $MRNA $SLS $LLY $REGN ABcellera 🔥 🔥 UPGRADES!!! BOOM!! Price targets (👀New Upgrade JEFFERIES $21🎯 🔵 Truist Securities — $30 🔴 JonesTrading — $25 🟡 UBS — $18 🟢 JPMorgan — $17 🟣 BMO Capital — $15 🟠 Goldman Sachs — $13 🩵 Cantor Fitzgerald — $12 🩷 Stifel — $9 ABCL — ANALYST PRICE TARGETS (USD) Truist Securities: $12 → $30 (+150%) JonesTrading: $13 → $25 (+92.3%) UBS: $18 (New Coverage) JPMorgan: $17 (New Coverage) BMO Capital: $15 Goldman Sachs: $13 (New Coverage) Cantor Fitzgerald: $11 → $12 (+9.1%) Stifel: $8 → $9 (+12.5%) 👀🚨🔥JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on AbCellera Biologics and set a price target of $25.00. She’s actually a very accurate Analyst!! So this is a STRONG SIGNAL $25’ssss!
0 replies
Stocktradesmoon Nov 6, 6:57 PM 1 replies
UncleTomFlorida Nov 6, 6:53 PM
$ABCL I last sold $ABCL at $11.50 to pay a bill. Long term capital gains so add a theoretical discount to the bill for whatever tax bracket the sale might have pushed me into. So now, anytime the stock dips below $11.50, I am a buyer if I gave the cash, even if it’s önly a $4 fractional. I know this is silly. Given the price of the stock, the quality of the company, a realistic price target of $15, a few pennies one way or another on a purchase this small is just not going to move the needle at all in any of my accounts. Stiil, thrift and value buying are essential skills in building wealth. Skills come from practice to the point of their being habitual. And so I continue to watch the pennies.
1 replies
Stocktradesmoon Nov 6, 6:00 PM 0 replies